Revive Therapeutics Ltd. (RVV)

Revive Therapeutics Logo White

Revive Therapeutics

CSE: RVV | OTC: RVVTF 

Revive Therapeutics is focused on the R&D and sale of cannabinoid-based products, recently expanding into the psychedelics industry more broadly.

Revive Therapeutics
$0.4800
0.00%
$0.0000

Latest News

Revive Therapeutics Signs MOU with Attwill Medical Solutions for Phase 3 Clinical Trial for Bucillamine in COVID-19

August 14, 2020

Revive Therapeutics Advancing Drug Delivery Technology for Psychedelics

August 11, 2020

Revive Therapeutics Update Following U.S. FDA Approval of Phase 3 Clinical Trial for Bucillamine in COVID-19

August 5, 2020

Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19

July 31, 2020

Revive Therapeutics Announces Submission of Investigational New Drug Application (IND) with U.S. FDA for Phase 3 Confirmatory Study for Bucillamine in COVID-19

June 30, 2020

Revive Therapeutics Expands Research Partnership for Novel Formulation Development and Clinical Research of Psilocybin with the University of Wisconsin-Madison

June 12, 2020

Join our Newsletter

Get the latest Company updates delivered to straight to your inbox.